下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)
文檔簡介
1、 HYPERLINK https:/www.MedChemE/Targets/IRAK.html IRAKInterleukin-1 receptor associated kinase; IL-1R associated kinaseInterleukin-1 receptor-associated kinases (IRAKs), are serine/threonine kinases, play critical roles in initiating innate immuneresponses against foreign pathogens and other types of
2、 dangers through their role in Toll-like receptor (TLR) and interleukin 1receptor (IL-1R) mediated signaling pathways. The four different IRAK-like molecules have been identified: two active kinases,IRAK-1 and IRAK-4, and two inactive kinases, IRAK-2 and IRAK-M. All IRAKs mediate activation of nucle
3、ar factor-kappaB (NF-B)and mitogen-activated protein kinase (MAPK) pathways.Toll-like receptors transduce their signals through the adaptor molecule MyD88 and members of the IL-1R-associated kinase family(IRAK-1, 2, M and 4). IRAK-1 and IRAK-2, known to form Myddosomes with MyD88-IRAK-4, mediate TLR
4、7-induced TAK1-dependentNF-B activation. IRAK-M is known to function as a negative regulator that prevents the dissociation of IRAKs from MyD88, therebyinhibiting downstream signalling.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/IRAK.html IRAK HYPERLINK https:/www.MedChemE/Targets/IRAK.html
5、 HYPERLINK https:/www.MedChemE/Targets/IRAK.html Inhibitors HYPERLINK https:/www.MedChemE/Targets/IRAK.html HYPERLINK https:/www.MedChemE/Targets/IRAK.html & HYPERLINK https:/www.MedChemE/Targets/IRAK.html HYPERLINK https:/www.MedChemE/Targets/IRAK.html Modulators HYPERLINK https:/www.MedChemE/as244
6、4697.html AS2444697 HYPERLINK https:/www.MedChemE/as2444697.html HYPERLINK https:/www.MedChemE/AZ1495.html AZ1495Cat. No.: HY-18992 Cat. No.: HY-111101AS2444697 is an orally active IRAK-4 inhibitor withan IC of 21 nM. AS2444697 potently inhibits50human and rat IRAK-4 activity. AS2444697 exhibitsreno
7、protective effects through anti-inflammatoryaction.AZ1495 (compound 28) is an oral active inhibitorof Interleukin-1 receptor associated kinase 4(IRAK4), with IC values of 5 nM and 23 nM for50IRAK4 and IRAK1, respectively. Shows activity intreatment of mutant MYD88L265P diffuse largeB-cell lymphoma (
8、DLBCL).Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.18%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/ca-4948-1.html CA-4948Cat. No.: HY-135317 HYPERLINK https:/www.MedChemE/Ginsenoside-Rb1.html G
9、insenoside HYPERLINK https:/www.MedChemE/Ginsenoside-Rb1.html HYPERLINK https:/www.MedChemE/Ginsenoside-Rb1.html Rb1(Gypenoside III) Cat. No.: HY-N0039CA-4948 is a potent IRAK4/FLT3 inhibtor withanti-tumor activity.Ginsenoside Rb1, a main constituent of the root ofPanax ginseng, inhibits Na+, K+-ATP
10、aseactivity with an IC of 6.31.0 M. Ginsenoside50also inhibits IRAK-1 activation and phosphorylationof NF-B p65 .Purity: 99.96%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98.75%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100
11、 mg HYPERLINK https:/www.MedChemE/hg-12-6.html HG-12-6 HYPERLINK https:/www.MedChemE/hg-12-6.html HYPERLINK https:/www.MedChemE/hs271.html HS271Cat. No.: HY-123956 Cat. No.: HY-131903HG-12-6 is a type II inhibitor of IRAK4. HG-12-6shows preferential binding to unphosphorylatedinactive IRAK4 with an
12、IC of 165 nM. HG-12-6 can50modulate IRAK4 activity in autoimmunity andinflammation.HS271 is a highly potent, orally active andselective IRAK4 inhibitor, with an IC of 7.2 M.50HS271 exhibits superior enzymatic and cellularactivities, as well as excellent pharmacokineticproperties.Purity: 98%Clinical
13、Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.92%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/IRAK-inhibitor-1.html IRAK HYPERLINK https:/www.MedChemE/IRAK-inhibitor-1.html HYPERLINK https:/www.MedChemE/IRAK-inhibit
14、or-1.html inhibitor HYPERLINK https:/www.MedChemE/IRAK-inhibitor-1.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-1.html 1 HYPERLINK https:/www.MedChemE/IRAK-inhibitor-1.html HYPERLINK https:/www.MedChemE/irak-inhibitor-2.html IRAK HYPERLINK https:/www.MedChemE/irak-inhibitor-2.html HYPERLINK htt
15、ps:/www.MedChemE/irak-inhibitor-2.html inhibitor HYPERLINK https:/www.MedChemE/irak-inhibitor-2.html HYPERLINK https:/www.MedChemE/irak-inhibitor-2.html 2Cat. No.: HY-13275 Cat. No.: HY-13276IRAK inhibitor 1 is a potent IRAK-4 inhibitor withIC of 216 nM, is poorly active against JNK-1 and50JNK-2 wit
16、h IC of 3.801 M, and 10 M,50respectively.IRAK inhibitor 2 is interleukin-1 receptorassociated kinase inhibitor .Purity: 98.05%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mgPurity: 98.87%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg HYPERLINK h
17、ttps:/www.MedChemE/IRAK-inhibitor-3.html IRAK HYPERLINK https:/www.MedChemE/IRAK-inhibitor-3.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-3.html inhibitor HYPERLINK https:/www.MedChemE/IRAK-inhibitor-3.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-3.html 3 HYPERLINK https:/www.MedChemE/IRAK
18、-inhibitor-3.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4.html IRAK HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4.html inhibitor HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4.html 4Cat. N
19、o.: HY-13277 Cat. No.: HY-13278IRAK inhibitor 3 is an interleukin-1 (IL-I)receptor-associated kinase (IRAK) kinase modulatorextracted from patent WO2008030579 A2.IRAK inhibitor 4 is an interleukin-1 receptorassociated kinase 4(IRAK4) inhibitor.Purity: 98.17%Clinical Data: No Development ReportedSize
20、: 10 mM 1 mL, 5 mg, 10 mg, 50 mgPurity: 99.77%Clinical Data: No Development ReportedSize: 5 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4-trans.html IRAK HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4-trans.html HYPERLINK https:/www.MedCh
21、emE/IRAK-inhibitor-4-trans.html inhibitor HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4-trans.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4-trans.html 4 HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4-trans.html HYPERLINK https:/www.MedChemE/IRAK-inhibitor-4-trans.html trans HYPERLINK https:/w
22、ww.MedChemE/IRAK-inhibitor-4-trans.html HYPERLINK https:/www.MedChemE/irak-inhibitor-6.html IRAK HYPERLINK https:/www.MedChemE/irak-inhibitor-6.html HYPERLINK https:/www.MedChemE/irak-inhibitor-6.html inhibitor HYPERLINK https:/www.MedChemE/irak-inhibitor-6.html HYPERLINK https:/www.MedChemE/irak-in
23、hibitor-6.html 6Cat. No.: HY-13278A Cat. No.: HY-13280IRAK inhibitor 4 (trans) is the trans form of IRAKinhibitor 4. IRAK inhibitor 4 is an interleukin-1receptor associated kinase 4 (IRAK4) inhibitor.IRAK inhibitor 6 is an inhibitor of interleukin-1receptor associated kinase 4 (IRAK-4) with IC of501
24、60 nM.Purity: 99.09%Clinical Data: No Development ReportedSize: 5 mgPurity: 99.75%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg HYPERLINK https:/www.MedChemE/IRAK-1-4-Inhibitor-I.html IRAK-1-4 HYPERLINK https:/www.MedChemE/IRAK-1-4-Inhibitor-I.html HYPERLINK https:/www.M
25、edChemE/IRAK-1-4-Inhibitor-I.html Inhibitor HYPERLINK https:/www.MedChemE/IRAK-1-4-Inhibitor-I.html HYPERLINK https:/www.MedChemE/IRAK-1-4-Inhibitor-I.html I(IRAK-1/4 Inhibitor I) Cat. No.: HY-13329 HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html IRAK-4 HYPERLINK https:/www.MedC
26、hemE/irak-4-protein-kinase-inhibitor-2.html HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html protein HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html kinase HYPERLINK https:/www.MedChemE/irak
27、-4-protein-kinase-inhibitor-2.html HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html inhibitor HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html HYPERLINK https:/www.MedChemE/irak-4-protein-kinase-inhibitor-2.html 2Cat. No.: HY-77048IRAK-1-4 Inhibitor I is an in
28、hibitor ofinterleukin-1 receptor-associated kinase 1/4 (IRAK1/4) with IC s of 0.2 M and 0.3 M,50respectively.IRAK-4 protein kinase inhibitor 2 (compound 1) isa potent inhibitor of interleukin-1 (IL-1)receptor-associated kinase-4 (IRAK-4), with an ICof 4 M. IRAK-4 protein kinase inhibitor 2 can beuse
29、d for the research of inflammatory andimmune-related conditions or disorders.50Purity: 99.88%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.48%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 10 mg HYPERLINK https:/www.MedChemE/IRAK4-IN-1.html IRAK4-IN-1 HYPE
30、RLINK https:/www.MedChemE/IRAK4-IN-1.html HYPERLINK https:/www.MedChemE/irak4-in-4-1.html IRAK4-IN-4Cat. No.: HY-101922 Cat. No.: HY-114181IRAK4-IN-1 is an interleukin-1 receptor associatedkinase 4 (IRAK4) inhibitor with an IC of 7 nM.50IRAK4-IN-4 is an interleukin-1 receptor-associatedkinase 4 (IRA
31、K4) inhibitor extracted from patentCN107163044A, Compound15, has an IC of 2.8 nM.50IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase(cGAS) with an IC of 2.1 nM.50Purity: 99.0%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 99.72%Clinical Data: No
32、 Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/irak4-in-6.html IRAK4-IN-6 HYPERLINK https:/www.MedChemE/irak4-in-6.html HYPERLINK https:/www.MedChemE/CA-4948.html IRAK4-IN-7Cat. No.: HY-130253 Cat. No.: HY-109585IRAK4-IN-6 is an orally efficaci
33、ous and selectiveIRAK4 inhibitor with an IC of 4 nM, and targetes50MyD88 L265P mutant diffuse large B cell lymphoma.IRAK4-IN-7 is a selective, potent and orallyactive interleukin-1 receptor-associated kinase 4(IRAK4) inhibitor, extracted from patentWO2015104688 (example 1). IRAK4-IN-7 has thepotenti
34、al for cancer and inflammatory diseasestreatment.Purity: 99.92%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 99.86%Clinical Data: Phase 1Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/irak4-in-8.html IRAK4-IN-8 HYPERLINK
35、https:/www.MedChemE/irak4-in-8.html HYPERLINK https:/www.MedChemE/jh-x-119-01.html JH-X-119-01Cat. No.: HY-143231 Cat. No.: HY-103017AIRAK4-IN-8 (VI-177) is a potent IRAK4 inhibitor.JH-X-119-01 is a potent and selectiveinterleukin-1 receptor-associated kinases 1 (IRAK1)inhibitor. JH-X-119-01 amelior
36、ates LPS-inducedsepsis in mice.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.0%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/JH-X-119-01_hydrochloride.html JH-X-119-01 HYPERLINK https:/www.MedCh
37、emE/JH-X-119-01_hydrochloride.html HYPERLINK https:/www.MedChemE/JH-X-119-01_hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/JH-X-119-01_hydrochloride.html HYPERLINK https:/www.MedChemE/pf-06426779.html PF-06426779Cat. No.: HY-103017 Cat. No.: HY-123854JH-X-119-01 hydrochloride is a p
38、otent andselective interleukin-1 receptor-associatedkinases 1 (IRAK1) inhibitor. JH-X-119-01hydrochloride ameliorates LPS-induced sepsis inmice.PF-06426779 is a potent and selective inhibitor ofinterleukin1 receptor associated kinase 4 (IRAK4),with an IC of 0.3 nM.50Purity: 89.79%Clinical Data: No D
39、evelopment ReportedSize: 10 mM 1 mL, 1 mg, 5 mg, 10 mg, 50 mgPurity: 99.83%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg HYPERLINK https:/www.MedChemE/protac-irak4-degrader-1.html PROTAC HYPERLINK https:/www.MedChemE/protac-irak4-degrader-1.html HYPERLINK https:/www.MedChemE/
40、protac-irak4-degrader-1.html IRAK4 HYPERLINK https:/www.MedChemE/protac-irak4-degrader-1.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-1.html degrader-1 HYPERLINK https:/www.MedChemE/protac-irak4-degrader-1.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-3.html PROTAC HYPERLINK h
41、ttps:/www.MedChemE/protac-irak4-degrader-3.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-3.html IRAK4 HYPERLINK https:/www.MedChemE/protac-irak4-degrader-3.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-3.html degrader-3Cat. No.: HY-129966 Cat. No.: HY-135382APROTAC IRAK4 degrad
42、er-1 is a Cereblon-based PROTACinterleukin-1 receptor-associated kinase 4 (IRAK4)degrader extracted from patent US20190192668A1Compound I-210, makes 20-50%, and50% IRAK4 degradation at 0.01, 0.1, and 1 Min OCI-LY-10 cells, respectively.PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4degrader based
43、on von Hippel-Lindau.Purity: 99.55%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/protac-irak4-degrader-4.html PROTAC HYPERLINK https:/www.MedChemE/protac-irak4-degrader-4.ht
44、ml HYPERLINK https:/www.MedChemE/protac-irak4-degrader-4.html IRAK4 HYPERLINK https:/www.MedChemE/protac-irak4-degrader-4.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-4.html degrader-4 HYPERLINK https:/www.MedChemE/protac-irak4-degrader-4.html HYPERLINK https:/www.MedChemE/protac-irak4-d
45、egrader-5.html PROTAC HYPERLINK https:/www.MedChemE/protac-irak4-degrader-5.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-5.html IRAK4 HYPERLINK https:/www.MedChemE/protac-irak4-degrader-5.html HYPERLINK https:/www.MedChemE/protac-irak4-degrader-5.html degrader-5Cat. No.: HY-139315 Cat. N
46、o.: HY-139316PROTAC IRAK4 degrader-4 is a Cereblon-based PROTACas interleukin-1 receptor-associated kinase 4(IRAK4) degrader extracted from patentUS20190192668A1, compound I-127.PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4degrader extracted from patent US20190192668A1,compound I-171.Purity: 98%Clinic
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 火炬蒸汽系統(tǒng)凝結(jié)水危害與改進探析
- 哲學(xué)講座觀眾電梯租賃合同
- 智能景區(qū)監(jiān)控安裝合同
- 便利店弱電系統(tǒng)工程合同
- 購物中心水電改造施工勞務(wù)合同
- 建筑機械工程合同管理辦法
- 建筑業(yè)貨車租賃合同協(xié)議書范本
- 住宅小區(qū)排水溝施工合同
- 商業(yè)中心簡易板房施工合同
- 港口碼頭外協(xié)隊施工合同
- 遠(yuǎn)離黃賭毒學(xué)習(xí)教案
- 北京市平谷區(qū)多校2024-2025學(xué)年三年級上學(xué)期期中競賽數(shù)學(xué)試卷
- 影響健康因素多 課件 2024-2025學(xué)年人教版(2024)初中體育與健康七年級全一冊
- 幼兒園轉(zhuǎn)課協(xié)議書范文范本
- 2023年銀行反洗錢知識競賽題庫及答案(120題)
- 廣東省深圳市寶安區(qū)2024-2025學(xué)年三年級上學(xué)期月考數(shù)學(xué)試卷(10月份)
- 2024年貴州省都勻市事業(yè)單位招聘5人高頻難、易錯點500題模擬試題附帶答案詳解
- 人教版六年級上冊道德與法治知識點
- 與薊州區(qū)幼兒園結(jié)對幫扶協(xié)議書(2篇)
- 第三次全國農(nóng)作物種質(zhì)資源普查與收集行動實施方案
- 安徽省2023-2024學(xué)年高一上學(xué)期期中考試物理試題(含答案)
評論
0/150
提交評論